Based on their ability to activate GLP-1 receptor, GLP-1R agonists can be classified as short-acting and long-acting GLP-1R agonists. Short-acting GLP-1R agonists are require to give either a once-daily (QD) or twice-daily (BID) dosing (e.g., Exenatide and Lixisenatide). Long-acting GLP-1R agonists have undergone some structural modifications to enhance their duration of action, while retaining their ability to act on the GLP-1 receptors (e.g., Albiglutide, Dulaglutide, once weekly).
GLP-1 New Drug R&D Service
Medicilon provides GLP-1 drug discovery, CMC research (API formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services.
1 view
4371
1523
2 months ago 00:25:06 1
You CAN Beat Diabetes & Insulin Resistance: Simple Hacks to Reverse It NOW! | Episode 8 of 18